Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1495870
Eisai Inc. - Strategic SWOT Analysis Review
Description:
Eisai Inc. - Strategic SWOT Analysis Review
Summary
Eisai Inc. (Eisai) is a pharmaceutical company with focus on the discovery, development and marketing of pharmaceutical products of unmet medical needs in the US. It is a subsidiary of Eisai Co., Ltd. The company's current products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux and Banzel for adjunctive treatment. It focuses on research activities in therapeutic areas such as neurology, gastrointestinal disorders, oncology and acute care. The company eastablished partnerships and collaborations with global companies such as Pfizer Inc., Janssen Pharmaceutica Inc., and Elan Pharma International Limited and Elan Pharmaceutical Inc for the development and distribution of drugs. Eisai is headquartered in New Jersey, the US.
Eisai Inc. Key Recent Developments
Jun 26, 2012: GSK, UCB And Eisai Form Joint Working Partnership For Epilepsy Care In NHS Dumfries and Galloway
Jun 22, 2012: Eisai Appoints Shaji Procida As CFO
Mar 07, 2011: Eisai Realigns US Operations
Jan 27, 2011: H3 Biomedicine Launches Research And Development Operations In Cambridge, Massachusetts
Our Eisai Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Our summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
Note: Some sections may be missing if data is unavailable for the company.
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with Our detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Summary
Eisai Inc. (Eisai) is a pharmaceutical company with focus on the discovery, development and marketing of pharmaceutical products of unmet medical needs in the US. It is a subsidiary of Eisai Co., Ltd. The company's current products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux and Banzel for adjunctive treatment. It focuses on research activities in therapeutic areas such as neurology, gastrointestinal disorders, oncology and acute care. The company eastablished partnerships and collaborations with global companies such as Pfizer Inc., Janssen Pharmaceutica Inc., and Elan Pharma International Limited and Elan Pharmaceutical Inc for the development and distribution of drugs. Eisai is headquartered in New Jersey, the US.
Eisai Inc. Key Recent Developments
Jun 26, 2012: GSK, UCB And Eisai Form Joint Working Partnership For Epilepsy Care In NHS Dumfries and Galloway
Jun 22, 2012: Eisai Appoints Shaji Procida As CFO
Mar 07, 2011: Eisai Realigns US Operations
Jan 27, 2011: H3 Biomedicine Launches Research And Development Operations In Cambridge, Massachusetts
Our Eisai Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Our summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
Note: Some sections may be missing if data is unavailable for the company.
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with Our detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Contents:
List of Tables
List of Figures
Section 1 - About the Company
Eisai Inc. - Key Facts
Eisai Inc. - Key Employees
Eisai Inc. - Major Products and Services
Eisai Inc. - Pharmaceutical Pipeline Products Data
Eisai Inc., Pipeline Products by Therapy Area
Eisai Inc., Pipeline Products by Development Phase
Eisai Inc. - History
Eisai Inc. - Company Statement
Eisai Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Eisai Inc. - Business Description
Eisai Inc. - SWOT Analysis
SWOT Analysis - Overview
Eisai Inc. - Strengths
Strength - Product Collaboration with Leading Players
Strength - Strong In-house Research Expertise
Strength - Synergy through Parent Company
Eisai Inc. - Weaknesses
Weakness - Legal Proceedings
Eisai Inc. - Opportunities
Opportunity - Agreements & Collaborations
Opportunity - Growing Market Opportunities in Emerging Markets
Opportunity - Business Expansions
Opportunity - Market Potential – Obesity
Eisai Inc. - Threats
Threat - Intense Competition
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Eisai Inc. - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
Eisai Inc., Recent Deals Summary
Section 4 – Company’s Recent Developments
Eisai Inc., Recent Developments
Jun 26, 2012: GSK, UCB And Eisai Form Joint Working Partnership For Epilepsy Care In NHS Dumfries and Galloway
Jun 22, 2012: Eisai Appoints Shaji Procida As CFO
Mar 07, 2011: Eisai Realigns US Operations
Jan 27, 2011: H3 Biomedicine Launches Research And Development Operations In Cambridge, Massachusetts
Section 5 – Appendix
Methodology
About Us
Contact Us
Disclaimer
List of Tables
Eisai Inc., Key Facts
Eisai Inc., Key Employees
Eisai Inc., Major Products and Services
Eisai Inc., Number of Pipeline Products by Therapy Area
Eisai Inc., Number of Pipeline Products by Development Stage
Eisai Inc., Pipeline Products By Therapy Area and Development Phase
Eisai Inc., History
Eisai Inc., Other Locations
Eisai Inc., Subsidiaries
Eisai Inc., Key Competitors
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
Eisai Inc., Recent Deals Summary
List of Figures
Eisai Inc., Pipeline Products by Therapy Area
Eisai Inc., Pipeline Products by Development Phase
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Eisai Inc., Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012
List of Figures
Section 1 - About the Company
Eisai Inc. - Key Facts
Eisai Inc. - Key Employees
Eisai Inc. - Major Products and Services
Eisai Inc. - Pharmaceutical Pipeline Products Data
Eisai Inc., Pipeline Products by Therapy Area
Eisai Inc., Pipeline Products by Development Phase
Eisai Inc. - History
Eisai Inc. - Company Statement
Eisai Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Eisai Inc. - Business Description
Eisai Inc. - SWOT Analysis
SWOT Analysis - Overview
Eisai Inc. - Strengths
Strength - Product Collaboration with Leading Players
Strength - Strong In-house Research Expertise
Strength - Synergy through Parent Company
Eisai Inc. - Weaknesses
Weakness - Legal Proceedings
Eisai Inc. - Opportunities
Opportunity - Agreements & Collaborations
Opportunity - Growing Market Opportunities in Emerging Markets
Opportunity - Business Expansions
Opportunity - Market Potential – Obesity
Eisai Inc. - Threats
Threat - Intense Competition
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Eisai Inc. - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
Eisai Inc., Recent Deals Summary
Section 4 – Company’s Recent Developments
Eisai Inc., Recent Developments
Jun 26, 2012: GSK, UCB And Eisai Form Joint Working Partnership For Epilepsy Care In NHS Dumfries and Galloway
Jun 22, 2012: Eisai Appoints Shaji Procida As CFO
Mar 07, 2011: Eisai Realigns US Operations
Jan 27, 2011: H3 Biomedicine Launches Research And Development Operations In Cambridge, Massachusetts
Section 5 – Appendix
Methodology
About Us
Contact Us
Disclaimer
List of Tables
Eisai Inc., Key Facts
Eisai Inc., Key Employees
Eisai Inc., Major Products and Services
Eisai Inc., Number of Pipeline Products by Therapy Area
Eisai Inc., Number of Pipeline Products by Development Stage
Eisai Inc., Pipeline Products By Therapy Area and Development Phase
Eisai Inc., History
Eisai Inc., Other Locations
Eisai Inc., Subsidiaries
Eisai Inc., Key Competitors
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
Eisai Inc., Recent Deals Summary
List of Figures
Eisai Inc., Pipeline Products by Therapy Area
Eisai Inc., Pipeline Products by Development Phase
Eisai Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Eisai Inc., Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012
Companies Mentioned
Abraxis BioScience, Inc.
Salix Pharmaceuticals, Ltd.
AstraZeneca PLC
Koronis Pharmaceuticals, Inc.
Predictive Biosciences, Inc.
Ceregene, Inc.
Adlyfe Inc.
Salix Pharmaceuticals, Ltd.
AstraZeneca PLC
Koronis Pharmaceuticals, Inc.
Predictive Biosciences, Inc.
Ceregene, Inc.
Adlyfe Inc.
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1495870
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Tuesday, June 18, 2013
7:41:47 AM
7:41:47 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Eisai Inc. - Strategic SWOT Analysis Review
Web Address
http://www.researchandmarkets.com/reports/1495870
Office Code
OC8DIQQNPVNTPU
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price |
|---|---|---|
| Electronic (PDF) - Single User |
|
EUR 96 |
| Electronic (PDF) - Site License |
|
EUR 191 |
| Electronic (PDF) - Enterprisewide |
|
EUR 287 |
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Tuesday, June 18, 2013
7:41:47 AM
7:41:47 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp